As the market makes an attempt to move upward, there is a clear preference for sectors that are focused on the domestic market. Given this,...

In just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...

Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...

Telangana is charting a new course to elevate Hyderabad into a global drug discovery hub. The state is fostering an integrated ecosystem by...

As the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

The government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defenc...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Emcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...